Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
about
Recent advances in treatment of heart failureEffect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial.Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial.Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing.Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditisResting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes?Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization.Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.Carvedilol: use in chronic heart failure.Beta-blocker therapy of heart failure: an update.Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.Beta-blocker use for the stages of heart failure.Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.Heart rate reduction in cardiovascular disease and therapy.Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.Is heart rate a treatment target in heart failure?Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?Heart rate reduction in heart failure: ivabradine or beta blockers?Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties.Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results.Beta-adrenergic receptor antagonists and chronic heart failure in children.Ivabradine in Management of Heart Failure: a Critical Appraisal.Heart rate and its reduction in chronic heart failure and beyond.Ivabradine for the treatment of chronic heart failure.Is heart rate reduction more important than target dose in chronic heart failure therapy with a beta-blocker?Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure.La fréquence cardiaque au repos : Un indicateur pronostique modifiable du risque et des issues cardiovasculaires ?Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Preliminary Randomized Prospective Study.Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.Heart rate in heart failure with preserved ejection fraction: target or marker?Adherence to the Mediterranean dietary pattern and heart rate in the SUN project.Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure.Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine.Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial
P2860
Q26766223-47E0ADF1-6BA7-446F-A6CB-961DEBBD1AF4Q30772422-42A01998-64F0-474C-ABCB-9D22B4171EFDQ30837563-58E4D9B0-81F6-4849-9DAD-34E8A50F353AQ31094492-12E3E05E-4DBA-47B4-A41D-04346D015A77Q34125706-0C110C12-1006-4481-A08D-7647B85FC83BQ34326097-C5FE3266-223F-4BF5-AA43-2A2ECEDEAFC9Q34774214-A4739562-1498-4FE6-BABA-876FEDBD3577Q36085763-E5D2E01C-2438-4171-B023-05996E9C9AE6Q36094414-6762FBE8-50AC-485F-AE76-F26552E3F265Q36094884-B8E808CC-0B37-47AF-8682-3965C79B24ACQ36691623-E48B2556-4BCF-4249-82BA-6889BD5D600BQ36723828-A58E9D87-4B60-47FB-8513-B604486EF043Q36961345-32C103C3-B51A-42B9-BC7B-C37D74A37F17Q37285564-C1C7E355-5A38-4C05-B687-9BB02D11F821Q37394083-EA025005-7103-447D-B2B3-273975447027Q37784463-4EB8BF9D-8364-4AEA-A88B-79B73D253A07Q37986643-81FEA2CD-AB8A-474C-BAF6-D56B32AFD82DQ37992528-011AE928-508C-4EA7-A069-1E17C4AE64E0Q38012561-0A01EE33-9B04-41CE-8846-C4DBA6E502E7Q38042855-CB04CF04-21F9-4CB5-A175-24A09519D355Q38127568-5F4688A8-61E2-4D8F-A7CE-2B341F71A16FQ38279998-DC5ACBFC-80E3-416B-937F-C934112CCF3DQ38288408-6AB5CDB8-8EA6-4789-9189-E3928D9B0234Q38546740-51FACD1D-8187-44E7-A1DB-F59551E6351DQ38669556-E186B808-4226-4DD5-A987-76EF33DBA327Q38769814-374BEE61-0D8A-4B84-AF74-2B6D8A14F6C9Q42226118-AEC4A98F-833D-4B74-9BB3-FCF8C822BEB7Q44264874-9A6B58DC-F32B-4E98-A7BE-21748D88AB5BQ44971239-FE7D7344-EA12-4C0A-841E-8F3662674316Q45733746-A99D6E79-81FF-4602-89A3-06ED934C90C4Q45913258-EA9F2FA1-6BB7-4E62-83E9-0C85CF167870Q48671978-4EBE3668-B8F8-4D72-807C-A8F5E09DFA58Q49044088-0DF4E5BA-F8E5-432F-895A-FC06E237447FQ50167513-0B3B02CB-B2BC-45F9-92F3-3D474FDCA500Q50897496-8878052C-E3B0-461F-B021-608CCCB9C7F3Q51566120-A8FF9AA6-3048-4D9F-A1D3-05A77FDAAFF1Q52686636-C87B1A3B-5FC3-4A35-A3B3-A95F743C3A97Q52739063-63D89FCB-0BE8-4286-B211-6B71D6BA100BQ53637670-4AB8A47D-6FE1-49F4-81D4-AB7A6F01B72EQ56958327-0A580C82-1D81-4F8A-ADAB-7F713D2CA788
P2860
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Influence of heart rate, blood ...... results from the COMET trial.
@en
Influence of heart rate, blood ...... results from the COMET trial.
@nl
type
label
Influence of heart rate, blood ...... results from the COMET trial.
@en
Influence of heart rate, blood ...... results from the COMET trial.
@nl
prefLabel
Influence of heart rate, blood ...... results from the COMET trial.
@en
Influence of heart rate, blood ...... results from the COMET trial.
@nl
P2093
P2860
P50
P921
P356
P1476
Influence of heart rate, blood ...... results from the COMET trial.
@en
P2093
Andrea Di Lenarda
Andrew Charlesworth
Armin Scherhag
Beatrix Lutiger
Mary Ann Lukas
Philip A Poole-Wilson
Willem J Remme
P2860
P304
P356
10.1093/EURHEARTJ/EHI386
P577
2005-07-21T00:00:00Z